|
|
- 2018
RSK3及其生物学功能
|
Abstract:
摘要 核糖体S6激酶3(RSK3)具有丝氨酸/苏氨酸激酶活性,在人体组织中广泛表达.RSK3属于90 ku的RSK家族,可通过促蛋白磷酸化作用在Ras-MAPK和PI3K-mTOR下游通路中作为重要的一级效应分子参与细胞增殖、细胞周期、细胞存活和分化等多方面的调控.简述RSK3的结构、表达、细胞中的调控机制与功能及其与疾病之间的关系.
| [1] | MORITZ A, LI Y, GUO A, et al.Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases[J]. Sci Signal, 2010, 3(136): a64. |
| [2] | BIGNONE P A, LEE K Y, Liu Y, et al.RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer[J]. Oncogene, 2007, 26(5): 683-700. |
| [3] | ROMEO Y, ZHANG X, ROUX P P.Regulation and function of the RSK family of protein kinases[J]. Biochem J, 2012, 441(2): 553-569. |
| [4] | SMITH J A, POTEET-SMITH C E, XU Y, et al. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation[J]. Cancer Res, 2005, 65(3): 1027-1034. |
| [5] | JAGILINKI B P, CHOUDHARY R K, THAPA P S, et al.Functional basis and biophysical approaches to characterize the C-terminal domain of human-ribosomal S6 kinases-3[J]. Cell Biochem Biophys, 2016, 74(3): 317-325. |
| [6] | LOUIS-JEUNE C, ANDRADE-NAVARRO M A, Perez-Iratxeta C. Prediction of protein secondary structure from circular dichroism using theoretically derived spectra[J]. Proteins, 2012, 80(2): 374-381. |
| [7] | ZENIOU M, DING T, TRIVIER E, et al.Expression analysis of RSK gene family members: the RSK2 gene, mutated in Coffin-Lowry syndrome, is prominently expressed in brain structures essential for cognitive function and learning[J]. Hum Mol Genet, 2002, 11(23): 2929-2940. |
| [8] | ERIKSON E, MALLER J L.A protein kinase from Xenopus eggs specific for ribosomal protein S6[J]. Proc Natl Acad Sci USA, 1985, 82(3): 742-746. |
| [9] | ERIKSON E, MALLER J L.Purification and characterization of a protein kinase from Xenopus eggs highly specific for ribosomal protein S6[J]. J Biol Chem, 1986, 261(1): 350-355. |
| [10] | MEYUHAS O.Physiological roles of ribosomal protein S6: one of its kind[J]. Int Rev Cell Mol Biol, 2008, 268: 1-37. |
| [11] | MACKENZIE S J, BAILLIE G S, MCPHEE I, et al.ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions[J]. J Biol Chem, 2000, 275(22): 16609-16617. |
| [12] | CANALES J, VALENZUELA M, BRAVO J, et al.Helicobacter pylori Induced phosphatidylinositol-3-OH kinase/mTOR activation increases hypoxia inducible factor-1alpha to promote loss of cyclin D1 and G0/G1 cell cycle arrest in human gastric cells[J]. Front Cell Infect Microbiol, 2017, 7: 92. |
| [13] | PASSARIELLO C L, MARTINEZ E C, THAKUR H, et al.RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome[J]. J Mol Cell Cardiol, 2016, 93: 98-105. |
| [14] | DOEHN U, GAMMELTOFT S, SHEN S H, et al.p90 ribosomal S6 kinase 2 is associated with and dephosphorylated by protein phosphatase 2Cdelta[J]. Biochem J, 2004, 382(Pt 2): 425-431. |
| [15] | ANJUM R, BLENIS J.The RSK family of kinases: emerging roles in cellular signalling[J]. Nat Rev Mol Cell Biol, 2008, 9(10): 747-758. |
| [16] | GRESSNER A M, WOOL I G.The phosphorylation of liver ribosomal proteins in vivo. Evidence that only a single small subunit protein (S6) is phosphorylated[J]. J Biol Chem, 1974, 249(21): 6917-6925. |
| [17] | VASUDEVAN K M, BARBIE D A, DAVIES M A, et al.AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer[J]. Cancer Cell, 2009, 16(1): 21-32. |
| [18] | SAAL L H, JOHANSSON P, HOLM K, et al.Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity[J]. Proc Natl Acad Sci USA, 2007, 104(18): 7564-7569. |
| [19] | KALINSKY K, JACKS L M, HEGUY A, et al.PIK3CA mutation associates with improved outcome in breast cancer[J]. Clin Cancer Res, 2009, 15(16): 5049-5059. |
| [20] | WANG K, MCDEMOTT J D, SCHROCK A B, et al.Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations[J]. Ann Oncol, 2017, 28(4): 748-753. |
| [21] | SERRA V, EICHHORN P J, GARCIA-GARCIA C, et al.RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer[J]. J Clin Invest, 2013, 123(6): 2551-2563. |
| [22] | NOH E M, LEE Y R, CHAY K O, et al.Estrogen receptor alpha induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells[J]. Mol Med Rep, 2011, 4(2): 215-219. |
| [23] | ANTONUZZO L, DEL R M, BARUCCA V, et al.Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors[J]. Cancer Treat Rev, 2017, 57: 28-35. |
| [24] | TSENG H S, WANG Y F, TZENG Y M, et al.Aloe-emodin enhances tamoxifen cytotoxicity by suppressing Ras/ERK and PI3K/mTOR in breast cancer cells[J]. Am J Chin Med, 2017, 45(2): 337-350. |
| [25] | EBRAHIMI S, HOSSEINI M, SHAHIDSALES S, et al.Targeting the Akt/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer[J]. Curr Med Chem, 2017, 24(13): 1321-1331. |
| [26] | BORRIE S C, BERMS H, LEGIUS E, et al.Cognitive dysfunctions in intellectual disabilities: the contributions of the Ras-MAPK and PI3K-AKT-mTOR pathways[J]. Annu Rev Genomics Hum Genet, 2017, 18: 115-142. |
| [27] | RYBA D M, Li J, COWAN C L, et al.Long-term biased beta-arrestin signaling improves cardiac structure and function in dilated cardiomyopathy[J]. Circulation, 2017, 135(11): 1056-1070. |
| [28] | WONG W, GOEHRING A S, KAPILOFF M S, et al.mAKAP compartmentalizes oxygen-dependent control of HIF-1alpha[J]. Sci Signal, 2008, 1(51): a18. |
| [29] | PASSARIELLOassariello C L, LI J, DODGE-KAFKA K, et al.mAKAP-a master scaffold for cardiac remodeling[J]. J Cardiovasc Pharmacol, 2015, 65(3): 218-225. |
| [30] | PAWSON T, SCOTT J D.Protein phosphorylation in signaling-50 years and counting[J]. Trends Biochem Sci, 2005, 30(6): 286-290. |
| [31] | PTACEK J, SNYDER M.Charging it up: global analysis of protein phosphorylation[J]. Trends Genet, 2006, 22(10): 545-554. |
| [32] | DUNN J D, REID G E, Bruening M L.Techniques for phosphopeptide enrichment prior to analysis by mass spectrometry[J]. Mass Spectrom Rev, 2010, 29(1): 29-54. |
| [33] | MARTINEZ E C, PASSARIELLO C L, Li J, et al.RSK3: A regulator of pathological cardiac remodeling[J]. IUBMB Life, 2015, 67(5): 331-337. |
| [34] | BJORBAEK C, ZHAO Y, MOLLER D E.Divergent functional roles for p90rsk kinase domains[J]. J Biol Chem, 1995, 270(32): 18848-18852. |
| [35] | VIK T A, RYDER J W.Identification of serine 380 as the major site of autophosphorylation of Xenopus pp90rsk[J]. Biochem Biophys Res Commun, 1997, 235(2): 398-402. |
| [36] | ZHAO Y, BJIRBAEK C, WEREMOWICZ S, et al.RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: growth factor-stimulated kinase function and nuclear translocation[J]. Mol Cell Biol, 1995, 15(8): 4353-4363. |
| [37] | GEOURJON C, DELEAGE G.SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments[J]. Comput Appl Biosci, 1995, 11(6): 681-684. |
| [38] | HSIAO K M, CHOU S Y, SHIH S J, et al.Evidence that inactive p42 mitogen-activated protein kinase and inactive Rsk exist as a heterodimer in vivo[J]. Proc Natl Acad Sci U S A, 1994, 91(12): 5480-5484. |
| [39] | BONNI A, BRUNET A, WEST A E, et al.Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms[J]. Science, 1999, 286(5443): 1358-1362. |
| [40] | DOEHN U, HAUGE C, FRANK S R, et al.RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells[J]. Mol Cell, 2009, 35(4): 511-522. |
| [41] | JAGILINKI B P, GADEWAL N, MEHTA H, et al.Conserved residues at the MAPKs binding interfaces that regulate transcriptional machinery[J]. J Biomol Struct Dyn, 2015, 33(4): 852-860. |
| [42] | ROMEO Y, ZHANG X, ROUX P P.Regulation and function of the RSK family of protein kinases[J]. Biochem J, 2012, 441(2): 553-569. |
| [43] | ROUX P P, RICHARDS S A, BLENIS J.Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity[J]. Mol Cell Biol, 2003, 23(14): 4796-4804. |
| [44] | MCMANUS E J, COLLINS B J, ASHBY P R, et al.The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation[J]. EMBO J, 2004, 23(10): 2071-2082. |
| [45] | DAVIES A H, REIPAS K, HU K, et al.Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells[J]. Oncotarget, 2015, 6(24): 20570-20577. |
| [46] | ARONCHIK I, APPLETON B A, BASHAM S E, et al.Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers[J]. Mol Cancer Res, 2014, 12(5): 803-812. |
| [47] | TORCHIARO E, LORENZATO A, OLIVERO M, et al.Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism[J]. Oncotarget, 2016, 7(1): 712-728. |
| [48] | POOMAKKOTH N, ISSA A, ABDULRAHMAN N, et al.p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer[J]. J Transl Med, 2016, 14: 14. |
| [49] | STRAFORD A L, REIPAS K, HU K, et al.Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers[J]. Stem Cells, 2012, 30(7): 1338-1348. |
| [50] | CORTES J, IM S A, HOLGADO E, et al.The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies[J]. Cancer Treat Rev, 2017, 61: 53-60. |
| [51] | KRIZER M D, LI J, PASSARIELLO C L, et al.The scaffold protein muscle A-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure[J]. Circ Heart Fail, 2014, 7(4): 663-672. |
| [52] | OHLSEN K, DONAT S.The impact of serine/threonine phosphorylation in Staphylococcus aureus[J]. Int J Med Microbiol, 2010, 300(2/3): 137-141. |
| [53] | CARRIERE A, RAY H, BLENIS J, et al.The RSK factors of activating the Ras/MAPK signaling cascade[J]. Front Biosci, 2008, 13: 4258-4275. |
| [54] | HOLBOUM K P, ACHARYA K R.Cloning, expression and purification of the CCN family of proteins in Escherichia coli[J]. Biochem Biophys Res Commun, 2011, 407(4): 837-841. |
| [55] | PACE C N, SHAW K L. Linear extrapolation method of analyzing solvent denaturation curves[J]. Proteins, 2000, Suppl 4: 1-7. |
| [56] | MORA A, KOMANDER D, VAN AALTEN D M, et al. PDK1, the master regulator of AGC kinase signal transduction[J]. Semin Cell Dev Biol, 2004, 15(2): 161-170. |
| [57] | ESSIG K, HU D, GUIMARAES J C, et al.Roquin suppresses the PI3K-mTOR signaling pathway to inhibit T helper cell differentiation and conversion of treg to Tfr cells[J]. Immunity, 2017, 47(6): 1067-1082. |
| [58] | SAPKOTA G P, CUMMINGS L, NEWELL F S, et al.BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo[J]. Biochem J, 2007, 401(1): 29-38. |
| [59] | KAPILOFF M S, PIGGOTT L A, SADANA R, et al.An adenylyl cyclase-mAKAPbeta signaling complex regulates cAMP levels in cardiac myocytes[J]. J Biol Chem, 2009, 284(35): 23540-23546. |
| [60] | VARGAS M A, TIMAUER J S, GLIDDEN N, et al.Myocyte enhancer factor 2 (MEF2) tethering to muscle selective A-kinase anchoring protein (mAKAP) is necessary for myogenic differentiation[J]. Cell Signal, 2012, 24(8): 1496-1503. |
